Darunavir (Prezista®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000692
English
Authors' recommendations:
Darunavir (Prezista®) 100 mg/ml oral suspension, co-administered with low dose ritonavir, is recommended as an option for use within NHS Wales, in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients, as well as antiretroviral therapy-experienced paediatric patients from the age of 3 years and at least 15 kg body weight.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1383
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Sulfonamides
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.